Key Insights on Gross Profit: Sanofi vs Viatris Inc.

Sanofi vs. Viatris: A Decade of Gross Profit Insights

__timestamp	Sanofi	Viatris Inc.
Wednesday, January 1, 2014	21769000000	3669400000
Thursday, January 1, 2015	23942000000	4382200000
Friday, January 1, 2016	23995000000	4998500000
Sunday, January 1, 2017	24774000000	4976200000
Monday, January 1, 2018	24356000000	4572000000
Tuesday, January 1, 2019	25655000000	4444200000
Wednesday, January 1, 2020	25212000000	3796700000
Friday, January 1, 2021	26920000000	5575500000
Saturday, January 1, 2022	31697000000	6497000000
Sunday, January 1, 2023	31797000000	6438600000
Monday, January 1, 2024	31081000000

Data in motion

A Decade of Gross Profit: Sanofi vs. Viatris Inc.

In the competitive landscape of the pharmaceutical industry, understanding financial performance is crucial. Over the past decade, Sanofi and Viatris Inc. have showcased distinct trajectories in their gross profit margins. Sanofi, a global healthcare leader, has consistently outperformed Viatris Inc., with its gross profit peaking at approximately $31.8 billion in 2023, marking a 46% increase from 2014. In contrast, Viatris Inc., formed in 2020, has shown a steady growth, reaching around $6.4 billion in 2023, a significant rise from its 2014 figures. This comparison highlights Sanofi's robust market position and Viatris Inc.'s emerging potential. As the industry evolves, these insights provide a glimpse into the strategic maneuvers and market dynamics shaping these pharmaceutical giants.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025